BNP Paribas Financial Markets Has $409,000 Stock Holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

BNP Paribas Financial Markets increased its position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 100.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 71,104 shares of the biotechnology company’s stock after buying an additional 35,695 shares during the period. BNP Paribas Financial Markets owned 0.33% of Enanta Pharmaceuticals worth $409,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of ENTA. China Universal Asset Management Co. Ltd. bought a new position in Enanta Pharmaceuticals in the 4th quarter worth approximately $26,000. AlphaQuest LLC lifted its position in shares of Enanta Pharmaceuticals by 16.4% during the 4th quarter. AlphaQuest LLC now owns 22,260 shares of the biotechnology company’s stock worth $128,000 after buying an additional 3,137 shares during the period. Thrivent Financial for Lutherans acquired a new stake in shares of Enanta Pharmaceuticals during the 4th quarter worth about $254,000. Intech Investment Management LLC bought a new stake in Enanta Pharmaceuticals during the 4th quarter worth approximately $58,000. Finally, American Century Companies Inc. grew its holdings in Enanta Pharmaceuticals by 10.5% during the 4th quarter. American Century Companies Inc. now owns 36,962 shares of the biotechnology company’s stock worth $213,000 after acquiring an additional 3,501 shares during the last quarter. 94.99% of the stock is currently owned by institutional investors.

Enanta Pharmaceuticals Trading Up 1.0%

Enanta Pharmaceuticals stock opened at $5.81 on Monday. The stock’s 50 day moving average is $5.42 and its 200-day moving average is $6.40. Enanta Pharmaceuticals, Inc. has a 12 month low of $4.09 and a 12 month high of $17.24. The company has a market capitalization of $124.20 million, a price-to-earnings ratio of -1.17 and a beta of 0.81.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings data on Monday, May 12th. The biotechnology company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.04) by ($0.02). Enanta Pharmaceuticals had a negative return on equity of 75.53% and a negative net margin of 157.57%. The company had revenue of $14.93 million for the quarter, compared to analyst estimates of $15.96 million. As a group, equities research analysts predict that Enanta Pharmaceuticals, Inc. will post -4.65 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ENTA has been the topic of several recent research reports. JMP Securities reaffirmed a “market outperform” rating and issued a $21.00 target price on shares of Enanta Pharmaceuticals in a research note on Tuesday, February 11th. Wall Street Zen raised Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, February 19th. Finally, HC Wainwright reissued a “buy” rating and set a $18.00 price target on shares of Enanta Pharmaceuticals in a research report on Tuesday, February 11th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.25.

Enanta Pharmaceuticals Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.